In a phased rollout, the jabs eventually will be offered to those with a BMI of 35 or more and weight-related health problems ...

FDA称，礼来两款替尔泊肽成分GLP-1注射剂Zepbound和Mounjaro 2022年来一直因需求增长而供应短缺，现认定短缺问题解决。行业组织称，FDA的认定等于让药房停止配置和分发两款药的仿制药。

The change will expand access to the diabetes and weight-loss drugs. But it will also complicate the future of compounded ...

Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...

After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been ...

智通财经APP获悉，美国食品药品管理局(FDA)宣布，礼来公司(LLY.US)的畅销减肥和糖尿病药物Zepbound和Mounjaro的短缺问题已得到解决，这可能会对市场上流行的仿制品造成冲击。此前，由于药物短缺，FDA允许药房出售未经严格测试的仿制 ...

NHS says a quarter of a million people will be offered tirzepatide - brand name Mounjaro - after trials showed it helped obese participants lose a fifth of their body weight ...

NHS leaders consider phased roll out of Mounjaro obesity jab to combat high demand - Nearly a quarter of a million people are ...

在分析师评级方面，BMO Capital维持礼来的"优于大市"评级，对公司新任首席财务官Lucas Montarce表示信心。德意志银行和Cantor Fitzgerald也分别维持了公司的买入和增持评级。

据媒体报道，在评级暂停一段时间后，花旗银行恢复了对减肥药巨头礼来的评级，给予“买入”评级，目标价1060美元/股，理由是看好该公司的GLP-1产品线销售额前景，其中包括其畅销的有着“减肥神药”称号畅销减肥药物Zepbound，该药物的核心成分为替尔泊 ...

Initially approved to treat Type 2 diabetes, Ozempic and Mounjaro also can help people with Type 1 diabetes lose weight and control their blood sugar levels, a new study finds. Overweight or obese ...

A class of drugs that includes popular medications like Ozempic, Wegovy, Rybelsus (semaglutide) or Mounjaro and Zepbound (tirzepatide) has not only proven effective in treating weight loss and ...